Consistent with the SOL1 Phase III clinical trial advanced ovarian cancer patients with BRCA1/2 mutations who experience remission after initial platinum-containing treatment could benefit from olaparib [21]. This evidence concerns the gene BRCA1 and ovarian carcinoma.